Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay

1241.94 - 1266.317 Dr. Rana McKay

Yeah, you know, I think the big take home message is that, you know, you can't just like put somebody on their ADT and check out because what we saw from the PRONOUNCE study, which was actually designed to look at cardiovascular risk in people that were getting an agonist versus an antagonist. And in the context of the trial, they had very robust upfront cardiovascular risk assessment.